The Possibility for Immunotherapy in Liver Cancer

Agenus reveals promising survival rates for its immunotherapy in metastatic colorectal cancer, potentially transforming treatment for resistant patients.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Final analysis of the INTRIGUE trial shows ripretinib offers similar survival rates and better safety compared to sunitinib for advanced GIST patients.

New findings reveal that fixed-duration ibrutinib plus venetoclax offers long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia.